• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • Draft guidelines for Communication on Real-World Evidence (RWE) to support drug registration applications

Draft guidelines for Communication on Real-World Evidence (RWE) to support drug registration applications

Real-World Evidence
Thursday, 06 October 2022 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

Draft guidelines for Communication on Real-World Evidence (RWE) to support drug registration applications

Real-World Evidence China: draft guidelines on communication for real world evidence to support drug registration applications have now been published by the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE).

Highlights

  • These draft guidelines apply to communications when real-world evidence is used to support a drug registration application as key evidence to support efficacy and/or safety evaluation.
  • These draft guidelines are based on the trial Guidelines for Real World Evidence to Support Drug Development and Review (Trial) (No. 1, 2020), published by the NMPA on January 7, 2020. The latter introduced the provision for the use of real-world evidence to support drug registration requires adequate communication with the CDE was introduced to ensure that both parties agree on the use of real-world evidence and the conduct of real-world studies.
  • The overarching legislation concerning communication meetings was issued by the CDE on December 10, 2020 entitled “Management of Communication for Drug Development and Technical Review” (No. 48 of 2020). Whereas this draft guideline specifies the core issues to be discussed in communication when using real-world evidence to support registration applications, meeting material requirements, etc., and provides recommendations for applicants to carry out communication at key time points to enhance the efficiency of drug clinical development.
  • The new draft guideline provides a framework and direction for drug registration applicants on the core issues to be discussed in the communication process in four areas:
    • the necessity and feasibility of a real-world study pathway,
    • key elements of the study programme,
    • applicability of real-world data,
    • and transparency of the study.
  • According to the specific situation of the research, the drug registration applicant can apply to the CDE for a communication meeting in three stages:
    • before the implementation of the research,
    • during the research,
    • and before submitting the application for listing registration.
  • At the end of each meeting, the applicant is required to submit a finalized meeting memo, which will be included in the marketing registration application package.

Further information

Click here to read the full draft Guidelines for Communication of Real World Evidence to Support Drug Registration Applications (Draft for Comments).

If you would like to learn more about our registration and CRO services for pharmaceuticals, medical devices, IVDs, cosmetics, health foods, industrial or consumer goods contact Cisema.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

Electronic submission for China drug registration
Electronic submission for China drug registration applications
Import of small quantities also possible without CCC certificate
cosmetics-gmp
Cosmetics GMP Good Manufacturing Practices now in force in China

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • GB9706 standards for medical electrical equipment

    GB9706 standards for medical electrical equipment – implementation details clarified

    GB9706 standards are important reference guidel...
  • Microbial limits for non-sterile chemical drugs

    Microbial limits for non-sterile chemical drugs, API and excipients – new guidelines issued

    Microbial limits for non-sterile chemical drugs...
  • Medical Device Supplementary Notice Period

    China’s Medical Device Supplementary Notice Period reverts to a one-year period

    China’s Medical Device Supplementary Notice Per...
  • Dental adhesive products registration review guidelines

    Dental adhesive products registration review guidelines issued by the CMDE

    Dental adhesive products registration review gu...
  • China’s Toothpaste Supervision & Administration Regulation

    China’s New Toothpaste Supervision & Administration Regulation: A brief guide

    China’s Toothpaste Supervision & Administra...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP